RxDoctor Payments Data

Denisa Hagau, MD

Cardiovascular Disease · Mason City, IANPI 1861703910

Payments from drug & device makers

$802in general payments, 2019–2025

Across 41 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$318
  • Edwards Lifesciences$104
  • Novartis$67
  • Boston Scientific$50
  • E.r. Squibb & Sons, L.L.C.$42
  • Amgen$40
  • plus $181 from 9 others

What the payments were for

  • Food & beverage$802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$802 in reported general payments places this provider in the 35th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$131,175
Medicare patients
1,331
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban384$404,653
JardianceEmpagliflozin308$303,242
XareltoRivaroxaban80$83,008
Repatha SureclickEvolocumab100$73,303
Praluent PenAlirocumab114$62,928
FarxigaDapagliflozin Propanediol33$30,363
EntrestoSacubitril/Valsartan19$20,470
Dofetilide74$12,099
Metoprolol Succinate841$11,519
Torsemide379$5,894
Rosuvastatin Calcium348$5,420
Atorvastatin Calcium510$5,057
Isosorbide Mononitrate ErIsosorbide Mononitrate240$3,371
Losartan Potassium509$3,044
Potassium Chloride104$2,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$404,653384 claims
Boehringer IngelheimJardiance$32$303,242308 claims
Johnson & JohnsonXarelto$25$83,00880 claims
AstraZenecaFarxiga$16$30,36333 claims
NovartisEntresto$67$20,47019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →